Monopar Therapeutics (MNPR) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free MNPR Stock Alerts $0.63 -0.03 (-4.56%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMonopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meetingglobenewswire.com - April 18 at 8:00 AMMonopar files patent protecting its MNPR-101 radiopharma optimization findingsmsn.com - April 16 at 11:02 AMMonopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findingsfinance.yahoo.com - April 16 at 11:02 AMBuy Rating on Monopar Therapeutics: Promising Trials and Financial Stability Highlight Growth Potentialmarkets.businessinsider.com - April 11 at 6:37 PMMonopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patientsglobenewswire.com - April 10 at 8:00 AMMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developmentsfinance.yahoo.com - March 28 at 8:08 AMMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developmentsglobenewswire.com - March 28 at 7:00 AMMonpar Therapeutics Shares Rise 12% After Positive Preclinical Data for MNPR-101marketwatch.com - March 6 at 7:42 PMMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Programmarkets.businessinsider.com - March 5 at 9:54 AMMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Programglobenewswire.com - March 5 at 7:00 AMMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trialglobenewswire.com - February 27 at 7:00 AMMonopar Therapeutics Inccnn.com - February 24 at 5:00 PMDow Surges Over 150 Points; AerCap Posts Upbeat Earningsmarkets.businessinsider.com - February 23 at 10:58 AMWhat's Going On With Cancer-Focused Monopar Therapeutics Stock Today?msn.com - February 22 at 6:40 PMMonopar stock jumps 60% amid preclinical data for MNPR-101msn.com - February 22 at 12:39 PMMonopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancersfinance.yahoo.com - February 22 at 7:38 AMCrude Oil Moves Lower; Summit Therapeutics Shares Plummetbenzinga.com - February 20 at 3:02 PMMonopar Therapeutics Shares Surge on Australia Antibody-Trial Clearancemarketwatch.com - February 20 at 3:02 PMWhy Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?msn.com - February 20 at 3:02 PMmarketbeat.com - February 20 at 10:30 AMmarketbeat.com - February 20 at 10:22 AMMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancersfinance.yahoo.com - February 20 at 10:01 AMmarketbeat.com - February 20 at 9:51 AMmarketbeat.com - February 20 at 9:41 AMmarketbeat.com - February 20 at 9:36 AMMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancersglobenewswire.com - February 20 at 8:00 AMKyverna Therapeutics Increuters.com - February 10 at 3:30 AMMonopar Therapeutics Inc. (MNPR)finance.yahoo.com - January 7 at 5:23 PMMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developmentsfinance.yahoo.com - November 9 at 9:32 AMMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developmentsfinance.yahoo.com - November 9 at 9:32 AMMonopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programsfinance.yahoo.com - November 9 at 9:32 AMPromising Early Efficacy Results and Diverse Drug Development Portfolio Drive ‘Buy’ Rating for Monopar Therapeutics Incmarkets.businessinsider.com - November 3 at 7:06 AMMonopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meetingfinance.yahoo.com - November 1 at 8:11 AMMonopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conferencefinance.yahoo.com - October 10 at 7:57 AMMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 5 at 5:52 PMMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 5 at 7:12 AMMonopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developmentsfinance.yahoo.com - August 10 at 10:06 AMMonopar Provides Encouraging Camsirubicin Clinical Data Updatefinance.yahoo.com - August 8 at 7:39 AMMonopar Provides Encouraging Camsirubicin Clinical Data Updatefinance.yahoo.com - August 8 at 7:39 AMMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singaporefinance.yahoo.com - July 11 at 8:36 AMMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singaporefinance.yahoo.com - July 11 at 8:36 AMMonopar to Participate in the Radiopharma Forum by the Lake 2023finance.yahoo.com - June 21 at 10:19 AMMonopar to Participate in the Maxim Group’s Healthcare Virtual Conferencefinance.yahoo.com - June 14 at 9:41 AMHC Wainwright & Co. Reiterates Monopar Therapeutics (MNPR) Buy Recommendationmsn.com - June 1 at 8:19 PMMonopar Announces Encouraging Camsirubicin Phase 1b Trial Updatefinance.yahoo.com - June 1 at 10:18 AMMonopar Announces Encouraging Camsirubicin Phase 1b Trial Updatefinance.yahoo.com - June 1 at 10:18 AMmarketbeat.com - May 30 at 10:03 AMMonopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?finance.yahoo.com - May 29 at 1:59 PMExpert Ratings for Monopar Therapeuticsmarkets.businessinsider.com - May 15 at 2:00 PMHC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy Recommendationmsn.com - May 15 at 2:00 PM Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide MNPR Media Mentions By Week MNPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼0.000.36▲Average Medical News Sentiment MNPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼01▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AgeX Therapeutics News Eterna Therapeutics News Galera Therapeutics News Guardion Health Sciences News Purple Biotech News Moleculin Biotech News Imunon News Elevai Labs News Alterity Therapeutics News RedHill Biopharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldTrump is sounding the alarmPreserve GoldFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
